TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05858034

Intervention type: OTHER
Group type: OTHER
Intervention: Customized activity plan
Description: Clients with identified challenges to successful aging (pre-frail or frail on screening) will be invited to develop an individualized activity plan to increase mobility, strength, and stamina. Plans will combine activities to improve strength (resistance training), balance (balance exercises), and stamina, and establish weekly goals. Resistance bands and pedometers will be provided. Progress will be measured by self-reported adherence to the activity plan at week 2, 4, 8, 12 and 24 (assessed by telephone at weeks 2, 4, 8 and in person at week 12 and 24). Depression questionnaire (PHQ-9), fatigue screen, exhaustion questions, and SF-12, a measure of health-related quality of life, will be administered at baseline, week 12 and 24.

Intervention type: OTHER
Group type: OTHER
Intervention: Customized nutrition plan
Description: Participants with nutritional needs will have the option of meeting with a nutritionist to develop a personalized nutritional plan with a goal of improving diet quality and optimizing caloric intake. Progress will be measured as above.
Study: NCT05286879

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Navigator
Description: Linkage to services for OUD/SUD treatment including MOUD, Hepatitis C virus (HCV) testing and treatment; those not living with HIV infection will be provided access to PrEP services, and those living with HIV will receive assistance with gaining initial or continued access to ART services during the 6-month post-release intervention period

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mobile Health Unit
Description: Participants will receive HIV PrEP/ HIV ART, MOUD, harm reduction services on the MHU and or assistance from a community health worker in linking to appropriate community-based OUD and other medical and behavioral health providers across the 6 month post-release intervention period
Study: NCT04752683

Intervention type: OTHER
Intervention: MyBuddy Employee Wellbeing App
Description: The intervention is not being evaluated in this research study.~The MyBuddy app contains five core components to help employees track their wellbeing (assisting employers in managing their employees' wellbeing). The six core components are: (1) a 'Budometer' stress measure (measure to be validated); (2) working from home information and assessment designed to inform employees about the legal requirements and risks they and their employers are subject to when home working; (3) messaging service for employees to contact their HR department or their line manager; (4) a 'Think Room' forum for staff to discuss ideas; (5) an 'Appreciation Page' for staff to show appreciation for their colleagues; and (6) 'my hours this week' log to track the hours they have worked. A seventh element is available for HR departments demonstrating data for the employees (employees are aware that HR will be able to see their data).

Intervention type: OTHER
Intervention: MyBuddy Employee Wellbeing App
Description: The intervention is not being evaluated in this research study.~The MyBuddy app contains five core components to help employees track their wellbeing (assisting employers in managing their employees' wellbeing). The six core components are: (1) a 'Budometer' stress measure (measure to be validated); (2) working from home information and assessment designed to inform employees about the legal requirements and risks they and their employers are subject to when home working; (3) messaging service for employees to contact their HR department or their line manager; (4) a 'Think Room' forum for staff to discuss ideas; (5) an 'Appreciation Page' for staff to show appreciation for their colleagues; and (6) 'my hours this week' log to track the hours they have worked. A seventh element is available for HR departments demonstrating data for the employees (employees are aware that HR will be able to see their data).
Study: NCT04206059

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: A non-contrast brain MRI will be acquired for localizing EEG slow waves

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST)
Description: Quantitative sensory testing (QST) using increasing ramp thermal stimulation (32-52 ºC) will be delivered to compare arousal thresholds between conditions.
Study: NCT05172154

Intervention type: DIAGNOSTIC_TEST
Intervention: GlowTest COVID-19 Antigen Home Test Kit
Description: The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection

Intervention type: DIAGNOSTIC_TEST
Intervention: GlowTest COVID-19 Antigen Home Test Kit
Description: The Arion Bio GlowTest COVID-19 Antigen Home Test is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigens from individuals with or without symptoms or other epidemiological reasons to suspect a COVID-19 infection
Study: NCT05756998

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) (classic technique)
Description: During CS , placement of CuT380 IUD at the top of the uterine fundus with ring forceps or manually; before closing the uterine incision, the strings were placed in the lower uterine segment. If the cervix was closed, dilatation from above with ring forceps or manually. Strings passed through the cervix with ring forceps, then checking that IUD remains at the fundus of the uterus prior to closing the uterine incision. The surgeon took a good care not to include IUD strings within the sutures. Six weeks postpartum; Patients will be questioned for any symptoms of complications or side effects. Pelvic examination (per speculum) and transvaginal ultrasound will be performed. Patient satisfaction will be assessed: pain using (VAS score), missed threads.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Copper T380 IUD ( Paragard 380 A ,CooperSurgical, Inc. © 2022) ( New technique)
Description: During CS, the plunger will be removed, the introducer remains in place and the arms of the IUD were released to be in a transverse position. The introducer will be inserted in the cervical canal through the uterine incision, threads might be shortened if needed or if couldn't be advanced into the cervical canal, The introducer containing the IUD will be then pushed upwards , towards the uterine fundus.The IUD will be placed at the uterine fundus and the IUD will be stabilized at its fundal position by grasping the fundus between the thumb anteriorly and the other fingers posteriorly. The uterine incision was closed while the introducer is in situ , then the introducer will be removed vaginally at the end of CS. Six weeks postpartum; Patients will be followed as in the classic technique group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cesarian section
Description: Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment \& the fetus is extracted , followed by the placenta \& membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis \& closure of the abdomen in layers .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cesarian section
Description: Under general or spinal anathesia , the abdomen is opened in layers , the bladder is dissected downwards . The uterus is incised at its lower segment \& the fetus is extracted , followed by the placenta \& membranes . The CU T 380 IUD is inserted either by the classic technique or the standard technique . The uterus is closed in 2 layers by continous non - locked sutures .Proper hemostasis \& closure of the abdomen in layers .
Study: NCT05609578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib oral dose of 400 mg twice daily tablets
Description: oral dose of 400 mg twice daily tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib oral dose of 400 mg twice daily tablets
Description: oral dose of 400 mg twice daily tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib oral dose of 400 mg twice daily tablets
Description: oral dose of 400 mg twice daily tablets

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion once every 3 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion once every 3 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemotherapy: Pemetrexed
Description: IV infusion once every 3 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemotherapy: Pemetrexed
Description: IV infusion once every 3 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: IV infusion once every 3 weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: IV infusion once every 3 weeks
Study: NCT05227469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myofunctional therapy
Description: In order to confirm that the exercises are done for a sufficient time and are done correctly, the researcher will take video recordings from the participants and examine these recordings every other day. Respondents will be contacted when errors are detected.
Study: NCT06472700

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05145127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06741086
Description: For participants aged ≥12 years 300 milligrams(mg) subcutaneous (sc) loading dose followed by 150 mg sq once weekly (qw). 300 mg sc qw is prescribed for participants who meet dose escalation criteria.~For participants aged ≥6 to \<12 years is marstacimab 150 mg SC for initial loading dose followed by 75 mg SC QW. 150 mg sc qw is prescribed for participants who meet dose escalation criteria.
Study: NCT05195333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The exercise program
Description: The exercise program prepared for the 1st group gestational diabetes will be explained to the pregnant women by the physiotherapist and the exercises will be taught to the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The exercise program
Description: The same exercise program will be given to the participants only as a brochure and they will be asked to do 10 repetitions at home, 3 days a week, until the 34th week of pregnancy.
Study: NCT05769608

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat Dose 1
Description: lorundrostat Dose 1 once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lorundrostat Dose 2
Description: lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria
Study: NCT06176664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow oxygen
Description: Standard nasal cannula oxygen up to 2 liters/minute

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygen
Description: High-flow nasal cannula with heating and humidification up to 2 liters/kilogram/minute
Study: NCT05507242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab 210 mg for 20 weeks (5 doses in total, 4-week intervals), administered subcutaneously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection for 20 weeks (5 doses in total, 4-week intervals)
Study: NCT06557161

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: TBI
Description: The total dose of TBI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TMLI
Description: The total dose of TMLI is 12 Gy, administered on days -7, -6, and -5, with 2 Gy per fraction, twice daily, for a total of 6 fractions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: The total dose of cyclophosphamide is 120 mg/kg, administered over 2 days on days -4 and -3.
Study: NCT06390163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory-Motor Integration Training
Description: An exercise chain consisting of motor tasks, sensory stimuli and cognitive tasks will be created. Each session will include at least 3 motor tasks, 3 sensory stimuli and 3 cognitive tasks selected according to the patient's condition.
Study: NCT04003428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity Focused Ultrasound
Description: HIFU shots will be performed on the placental tissue to produce necrotic lesions of approximately 30% of the total volume. A latency time of 2 minutes between each shot will be observed to avoid the accumulative heat effect, and to ensure optimal positioning of the treatment probe. The maximum duration of the operating time for HIFU shooting shall not exceed 60 minutes.
Study: NCT05214118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: technology-based program
Description: Participants will be asked to complete three 25-minute modules covering the transition from pregnancy to postpartum, possible neonatal abstinence syndrome (NAS) or neonatal withdrawal syndrome (NOWS), and interactions with child welfare.
Study: NCT04466358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified CLOSE protocol
Description: Modified CLOSE protocol guided isolation of pulmonary veins.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High density mapping guided pulmonary vein isolation
Description: Modified CLOSE protocol guided isolation of pulmonary veins with additional ablations at sites of gaps or dormant conduction as evidenced by high density mapping of pulmonary vein antra.
Study: NCT06317987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Navigation
Description: Care navigation is an intervention that seeks to help patients follow up on substance use treatment plans that are established by care coordinators in the health system by reducing barriers to accessing treatment. This includes advocating for patients to reduce disparities based on language, income or geographical barriers, and cultural preferences (i.e., linkage to available services); and using motivational enhancement techniques to help patients maintain their motivation to obtain substance use treatment while working through these barriers (i.e., motivational intervention). Thus, the care navigator's role is to take the care plan developed between the patient and the mental health care coordinator forward and connect the patient to available services and provide motivational enhancement techniques to help direct the patient toward completion of the care plan.
Study: NCT06028412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sublobar
Description: The minimize unit is the subsegment, the subloar group includes wedge resection, subsegmentectomy, segmentectomy.~It is recommended to perform intraoperative lymph node pathology (not mandatory). If lymph node metastasis is positive, we must switch to lobectomy+system lymph node dissection. lymph node sampling, selective lymph node dissection or systematic lymph node dissection are allowed in this group.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lobectomy
Description: lobectomy+system lymph node dissection
Study: NCT06016608

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Angiography, Ocular OCTA, CT Angiography
Description: Magnetic Resonance Angiography of intracranial artery, carotid artery, renal artery and lower extremity artery, CT angiography of coronary artery or intracranial artery
Study: NCT06643481

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VHB937
Description: VHB937 solution for infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion
Study: NCT04923672

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate continuous exercise
Description: Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of continuous moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval exercise
Description: Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
Study: NCT05132491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TECH-Prep Intervention
Description: Participants in the treatment program will be asked to complete 10 online training modules (1 hour each), attend 5 online motivational speaker forums (1 hour each), and view 5 coding workshops. The activities will be completed over an 8 week period.
Study: NCT05749822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate 200mg
Description: Fenofibrate 200mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet/ day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UDCA
Description: UDCA 13-15mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA
Description: UDCA 13-15mg/kg/day
Study: NCT06536426

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Knee Isometric Program (KIP)
Description: The KIP physical therapy protocol follows the schedule outlined below:~* Session 1 (Completed 4-5 days/week including HEP): Double Leg wall sit 3x30 seconds, Double Leg glute bridge hold 3x30 seconds, Single Leg Stance hold 3x1 minutes, Lunge hold 3x1 minutes~* Session 2 (Completed 4-5 days/week including HEP): Single Leg wall sit 3x20 seconds, Single Leg glute bridge hold 3x20 seconds, Single Leg stance hold 2x1.5 minutes, Lunge hold 2x1.5 minutes~* Session 3 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes~* Session 4 (Completed 4-5 days/week including HEP): Single leg wall sit 3x40 seconds, Single leg glute bridge hold 3x40 seconds, Single leg stance hold 2x3 minutes, Lunge hold 2x3 minutes
Study: NCT06350110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19- BCMA CAR-T cells
Description: The intervention in this clinical trial involves a novel approach using CD19/BCMA-Chimeric Antigen Receptor T (CAR T) cells combined with chemotherapy. The goal is to assess safety and efficacy in patients with specific hematologic malignancies.~Treatment Regimen:~Patients in the trial will undergo the following regimen:~Fludarabine Phosphate (Days -4 to -2): IV administration of fludarabine phosphate over 30 minutes on days -4 to -2. It's part of the preparatory regimen to enhance the body's response to CAR T-cell therapy.~Cyclophosphamide (Day -2): IV cyclophosphamide over 60 minutes on day -2.~CD19/BCMA-Chimeric Antigen Receptor T Cells (Day 0): IV administration of investigational therapy, CD19/BCMA-CAR T cells, over 10-20 minutes on day 0.~Additional Doses: Eligible patients responding well to the initial CD19/BCMA-CAR T cell infusion without unacceptable side effects and sufficient CAR T cell availability may receive 2 or 3 additional doses.
Study: NCT05759767

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Children in this group will receive medical expulsive therapy in the form of (tamsulosin at a dose of 0.01 mg/kg once daily for 3 weeks after ESWL session.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children in this group will receive placebo once daily for 3 weeks after ESWL session.
Study: NCT06107699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Assigned a Patient Navigator to provide information on transitional care and community resources.
Study: NCT06567392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] HRS-5965
Description: Patients will receive single dose of orally \[14C\] HRS-5965 on Day 1.
Study: NCT04872439

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: Patients with autoimmune gastrointestinal dysmotility will provide 20 mL of blood to isolate serum, plasma and peripheral blood mononuclear cells for whole exome sequence. Antibodies to be isolated are: Antineuronal nuclear antibody type 1,Collapsing response-mediator family immunoglobulin G, Ganglionic Acetylcholine Receptor Antibody, Muscle Acetylcholine Receptor Antibody, Striational, Voltage-gated calcium channel, N- type, Voltage-gated calcium channel, P/Q- type, Voltage-gated potassium channel, Glutamic Acid Decarboxylase 65, Gastric parietal cell, Thyroperoxidase, Thyroglobulin
Study: NCT05646355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive CRC Screening Outreach
Description: Proactive approach that incorporates a mailed outreach invitation to screen with fecal immunochemical testing (FIT), followed by active assistance to colonoscopy completion if preferred or indicated by FIT test result.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will not receive additional outreach from the study team regarding CRC screening.
Study: NCT06387953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bridge Therapy
Description: After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Bridge therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Therapy
Description: After the patient has been intubated in the operating room - the Bridge device intervention will be applied to the subject's ear by a trained study team member. At the time of the pre-incision pause, Initiation of the intervention (Sham therapy) will begin and will be continued throughout the surgery. The intervention will continue for 24 hours after extubation.